Celera Diagnostics to use Luminex' xMAP technology:
This article was originally published in Clinica
Alameda, California-based Celera Diagnostics, a joint venture between Applied Biosystems and Celera Genomics, is to have worldwide, nonexclusive rights to develop and distribute in vitro diagnostic products based on Luminex' xMAP technology. Under the deal, Austin, Texas-based Luminex will gain royalties, as well as revenue from the sale of instruments and xMAP microspheres. "We believe the addition of Celera Diagnostics' future molecular tests to the growing list of commercial diagnostic assays can significantly expand the capabilities and acceptance of the Luminex xMAP technology," said Randy Marfin, vice-president of business development at Luminex.
You may also be interested in...
With Brexit less than a month old, Germany’s medtech industry has renewed its push for an MRA between the EU and UK in medtech regulation.
Days after a senior Chinese government official offered free COVID-19 vaccines to the Philippines government, the country’s medicines regulator said the donated jabs would need an emergency approval before they can be used on the public.
Interview: recently appointed CEO Richard Francis will apply his background in big pharma and biotech to building the UK start-up Purespring Therapeutics with a focus on using gene therapy technology to target renal diseases.